Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.
Sarcoma|Advanced Sarcoma|High Grade Sarcoma|Leiomyosarcoma|Undifferentiated Pleomorphic Sarcoma|Myxofibrosarcoma|Dedifferentiated Liposarcoma
DRUG: DCC-3014|DRUG: Avelumab
Maximum tolerated dose, Identify the maximum tolerated dose (MTD) by evaluating toxicity using NCI CTCAE (version 4.03), 1 year|Overall Response Rate, Best overall response rate (CR+PR) based on RECIST v1.1, 48 weeks
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.